直肠癌自适应放疗需求估算的两中心研究
本研究纳入中心1的66例和中心2的27例直肠癌患者,通过比较计划与治疗分次的8项剂量体积直方图指标评估自适应放疗需求,并利用18项特征建立逐步逻辑回归模型进行分次水平预测。模型训练集AUC为0.74(95%CI:0.61-0.85),内部测试集AUC为0.76(95%CI:0.60-0.90),外部测试集AUC为0.68(95%CI:0.56-0.81)。
要点
- 模型保留5项特征:均匀性指数、计划靶区体积、分次剂量、累积剂量及是否新辅助放化疗。
- 最佳截断值33.4%时敏感度46.2%、特异度97.9%;临床适用截断值11%时敏感度69.2%、特异度68.7%。
- 预测模型具备预测分次水平自适应放疗需求的能力。
核心结论
- 自适应放疗需求与靶区体积、靶区剂量均匀性、分次剂量、剂量累积及是否新辅助放疗相关。
- 预测模型表现出预测分次水平自适应放疗需求的能力。
研究设计与样本
- 本研究为两中心研究,纳入中心1的66例直肠癌患者和中心2的27例患者。
- 通过比较计划与治疗分次间靶区及危及器官的8项剂量体积直方图指标评估自适应放疗需求。
- 从10例患者导出剂量体积直方图指标偏差的耐受范围并用于评估分次间变异。
- 利用18项诊断、剂量学和时间相关特征建立逐步逻辑回归模型进行分次水平自适应放疗需求估算。
- 超参数通过5折交叉验证确定,训练分次250个,内部测试分次109个,外部测试分次134个。
主要发现
- 训练集AUC为0.74(95%CI:0.61-0.85),内部测试集AUC为0.76(95%CI:0.60-0.90),外部测试集AUC为0.68(95%CI:0.56-0.81)。
- 采用最佳截断值33.4%时,敏感度为46.2%,特异度为97.9%。
- 采用临床适用截断值11%时,敏感度为69.2%,特异度为68.7%。
- 建模中保留5项特征:均匀性指数(OR=6.06,95%CI:2.93-14.8)、计划靶区体积(OR=1.77,95%CI:1.17-2.69)、分次剂量(OR=45.37,95%CI:5.74-469)、累积剂量(OR=2.29,95%CI:1.35-4.14)及是否新辅助放化疗(OR>1000)。
关键数值与推荐
- 采用最佳截断值33.4%时,敏感度为46.2%,特异度为97.9%。
- 采用临床适用截断值11%时,敏感度为69.2%,特异度为68.7%。
- 均匀性指数OR=6.06(95%CI:2.93-14.8)。
- 计划靶区体积OR=1.77(95%CI:1.17-2.69)。
- 分次剂量OR=45.37(95%CI:5.74-469)。
临床怎么用
- 原文未据此给出临床推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Rectal cancer patients are potential beneficiaries of adaptive radiotherapy (ART) which demands considerable resources. Currently, there is no definite guidance on what kind of patients and when will benefit from ART. This study aimed to develop and validate a methodology for estimating ART requirements in rectal cancer before treatment course. METHODS AND MATERIALS: This study involved 66 rectal cancer patients from center 1 and 27 patients from center 2. The ART requirements were evaluated by comparing 8 dose volume histogram (DVH) metrics of targets and organs at risk (OARs) between planning and treatment fractions. Tolerance ranges of deviation of DVH metrics were derived from 10 patients and applied to assess fractional variability. Eighteen features, encompassing diagnostic, dosimetric, and time-related information, were utilized to formulate a stepwise logistic regression model for fraction-level ART requirement estimation. The super parameters were determined through 5-fold cross-validation with 250 training fractions and the methodology was validated with 109 internal testing fractions and 134 external testing fractions. RESULTS: The area under the curve (AUC) of training dataset was 0.74 (95% CI: 0.61 to 0.85), while in the internal and external testing, the AUC achieved 0.76 (95% CI: 0.60-0.90) and 0.68 (95% CI: 0.56-0.81). Using a best (or clinical applicable) cut-off value of 33.4% (11%), the predictive model achieved a sensitivity of 46.2% (69.2%) and specificity of 97.9% (68.7%). During the modeling, 5 features were retained: Homogeneity index (OR = 6.06, 95% CI: 2.93-14.8), planning target volume (OR = 1.77, 95% CI: 1.17-2.69), fraction dose (OR = 45.37, 95% CI: 5.74-469), accumulated dose (OR = 2.29, 95% CI: 1.35-4.14), and whether neoadjuvant chemoradiotherapy (OR > 1000). CONCLUSION: ART requirements are associated with target volume, target dose homogeneity, fraction dose, dose accumulation and whether neoadjuvant radiotherapy. The predictive model exhibited the capability to predict fraction-level ART requirements.
引用
- Chen L, Yu L, Luo H, et al. Estimation of adaptive radiation therapy requirements for rectal cancer: a two-center study. Radiat Oncol. 2024. PMID: 39695801. doi:10.1186/s13014-024-02567-7
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。